Lyell Immunopharma's market cap is currently $192.83M. The company's EPS TTM is $-0.801; its P/E ratio is ―; Lyell Immunopharma is scheduled to report earnings on February 26, 2025, and the estimated EPS forecast is $-0.17. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 130.00K	$ 84.68M	$ 10.65M	$ 7.76M	$ 657.00K
Gross Profit	$ 130.00K	$ 68.22M	$ -3.88M	$ 281.00K	$ 657.00K
Operating Income	$ -247.01M	$ -183.12M	$ -214.78M	$ -211.94M	$ -102.09M
EBITDA	$ -226.76M	$ -166.65M	$ -199.94M	$ -207.64M	$ -100.83M
Net Income	$ -234.63M	$ -4.75M	$ -285.50M	$ -198.53M	$ -121.26M
Balance Sheet
Cash & Short-Term Investments	$ 546.22M	$ 640.15M	$ 614.79M	$ 612.62M	$ 436.05M
Total Assets	$ 750.03M	$ 937.56M	$ 1.13B	$ 908.28M	$ 555.63M
Total Debt	$ 63.17M	$ 67.70M	$ 67.82M	$ 54.57M	$ 27.47M
Net Debt	$ -82.48M	$ -55.85M	$ -226.01M	$ -85.83M	$ -69.20M
Total Liabilities	$ 95.08M	$ 104.31M	$ 197.62M	$ 189.84M	$ 147.58M
Stockholders' Equity	$ 654.95M	$ 833.25M	$ 929.79M	$ 718.44M	$ 408.06M
Cash Flow
Free Cash Flow	$ -166.38M	$ -193.83M	$ -191.75M	$ -212.35M	$ 23.43M
Operating Cash Flow	$ -163.69M	$ -169.56M	$ -126.25M	$ -160.87M	$ 39.47M
Investing Cash Flow	$ 184.05M	$ -11.54M	$ -121.57M	$ -273.52M	$ -422.43M
Financing Cash Flow	$ 1.74M	$ 10.63M	$ 401.24M	$ 476.79M	$ 351.16M

Currency in USD

Lyell Immunopharma Earnings and Revenue History

Income Statement >

Lyell Immunopharma Debt to Assets

Balance Sheet >

Lyell Immunopharma Cash Flow

Cash Flow >

Lyell Immunopharma Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing